Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
20.17
-0.79 (-3.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hutchmed China Ltd ADR
< Previous
1
2
3
Next >
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
October 27, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
October 10, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED (China) Limited (NASDAQ:HCM) Investor Alert: Investigation over Potential Wrongdoing
June 08, 2022
San Diego, CA -- (SBWIRE) -- 06/08/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at HUTCHMED (China) Limited.
Via
SBWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
May 27, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
May 26, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages HUTCHMED (China) Limited Investors with Losses to Inquire About Class Action Investigation – HCM
May 26, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
NASDAQ:HCM Shareholder Notice: Investigation over Possible Securities Laws Violations by HUTCHMED (China) Limited
May 16, 2022
San Diego, CA -- (SBWIRE) -- 05/16/2022 -- HUTCHMED (China) Limited is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
August 08, 2021
From
Epizyme, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.